Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Are another 5 years of adjuvant aromatase inhibitor therapy needed?

Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and The...

Full description

Bibliographic Details
Main Authors: Mo QG, Li DQ, Zhong JH, Wei CY
Format: Article
Language:English
Published: Dove Medical Press 2016-11-01
Series:Breast Cancer : Targets and Therapy
Subjects:
breast cancer
adjuvant endocrine therapy
Online Access:https://www.dovepress.com/letter-adjuvant-systemic-therapy-in-older-women-with-breast-peer-reviewed-article-BCTT
id doaj-c9509be1c44c4aa980562fdec77f0543
record_format Article
spelling doaj-c9509be1c44c4aa980562fdec77f05432020-11-24T21:00:37ZengDove Medical PressBreast Cancer : Targets and Therapy1179-13142016-11-01Volume 820720930011Are another 5 years of adjuvant aromatase inhibitor therapy needed?Mo QGLi DQZhong JHWei CYQin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.View original paper by Leone and colleagues.https://www.dovepress.com/letter-adjuvant-systemic-therapy-in-older-women-with-breast-peer-reviewed-article-BCTTbreast canceradjuvant endocrine therapy
collection DOAJ
language English
format Article
sources DOAJ
author Mo QG
Li DQ
Zhong JH
Wei CY
spellingShingle Mo QG
Li DQ
Zhong JH
Wei CY
Are another 5 years of adjuvant aromatase inhibitor therapy needed?
Breast Cancer : Targets and Therapy
breast cancer
adjuvant endocrine therapy
author_facet Mo QG
Li DQ
Zhong JH
Wei CY
author_sort Mo QG
title Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_short Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_full Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_fullStr Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_full_unstemmed Are another 5 years of adjuvant aromatase inhibitor therapy needed?
title_sort are another 5 years of adjuvant aromatase inhibitor therapy needed?
publisher Dove Medical Press
series Breast Cancer : Targets and Therapy
issn 1179-1314
publishDate 2016-11-01
description Qin-Guo Mo*, De-Quan Li*, Jian-Hong Zhong, Chang-Yuan Wei Department of Breast Surgery, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, People’s Republic of China *These authors contributed equally to this workIn the recent issue of Breast Cancer: Targets and Therapy, some questions about adjuvant systemic therapy1 and bone loss and skeletal-related events in postmenopausal women with hormone receptor-positive breast cancer2 were discussed by two reviews.View original paper by Leone and colleagues.
topic breast cancer
adjuvant endocrine therapy
url https://www.dovepress.com/letter-adjuvant-systemic-therapy-in-older-women-with-breast-peer-reviewed-article-BCTT
work_keys_str_mv AT moqg areanother5yearsofadjuvantaromataseinhibitortherapyneeded
AT lidq areanother5yearsofadjuvantaromataseinhibitortherapyneeded
AT zhongjh areanother5yearsofadjuvantaromataseinhibitortherapyneeded
AT weicy areanother5yearsofadjuvantaromataseinhibitortherapyneeded
_version_ 1716779175215366144

Similar Items